Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$3.43
▼ $0.38 (-10.0%)
Market data updated: 09/26 09:44 AM
Fundamentals updated: 09/26/2026
News analyzed: 09/26/2026
Market Cap
$24.46M
Day Range
$3.37 - $3.85
52-Week Range
$1.87 - $6.93
Beta
—
Next Earnings
17.11.2026
Support
$2.56
Resistance
$4.25
GRDX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-27.2% (1Y)
Strengths: 8/24 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 74.0%
Growth
Biggest negative driver
Operating margin
Operating margin: -19540.0% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 3 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 3
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
49
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
20d ago · $3.25
Evidence: Narrative Gap moved from 15 to -20 day-over-day
What happened after
20d ago · $3.25
Evidence: Panic-selling score jumped from 7 to 32 day-over-day
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
66
Quality
No data available
Value
50
Momentum
67
Risk
26
Sentiment
50
Fundamental
18
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Based on the limited and indirect English-language news sources provided, recent media coverage for GridAI Technologies Corp. (NASDAQ: GRDX) has primarily focused on its Q2 2026 financial performance, highlighting a significant increase in losses per share (down 773.91% YoY to $2.01) and minimal sales ($85.876K). No direct company-specific updates beyond this financial report are evident in the sources, which otherwise focus on unrelated healthcare stocks.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about GridAI Technologies Corp.. News trend score: 50. Reason: The mix of positive and negative articles is balanced — 3 vs. 3 out of the last 6 articles.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
19
🎯 Conviction (vs. Emotion)
50
Psychology
64
Fundamentals
18
Technical
67
Valuation
50
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
-22%
Market Narrative
60
Fundamental Reality
50
Narrative Gap
+10
🔀 Weak-Conviction Rally
Price is moving, but not accompanied by a matching rise in news attention/sentiment.
🧠 StockIQ Psychologist
The market’s extreme loss aversion (score: 100) reflects deep psychological resistance to further declines, likely due to the 44.7% drop over three months. While panic selling (31) is present, it’s muted by modest volatility and neutral sentiment, preventing a full-blown selloff. The narrative gap (-20) hints at a disconnect where optimism may outpace fundamentals, but observable behavior remains anchored in past losses. The key question: Will traders hold or exit as the stock remains far from support?
Updated: 09/09/2026, 01:37 PM
What could change this?
📈 8D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 82/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
The stark divide in verdicts for GRDX reflects deep methodological contrasts: value-focused investors like Benjamin Graham (57) and his enterprising counterpart (56) see only modest discounts, while cyclical strategists like Samuel Armstrong Nelson (85) and Howard Marks (96) highlight its favorable position near cycle troughs. Meanwhile, contrarian voices like Jesse Livermore (17) and Morgan Housel (0) dismiss it outright—Livermore for its trend-defiance and Housel for its volatility, while behavioral economists like Veblen (13) and Loeb (13) flag it as either speculative or capital-threatening. The absence of strong signals for growth-driven investors (Lynch, Fisher) or dividend-focused ones (Smith) further isolates GRDX as a niche play, where only cyclical and risk-tolerant frameworks find merit.
Peter Lynch
One Up on Wall Street (1989)
🟢 100
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 82
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 81
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 59
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 57
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 56
Some discount, but not the deep 'net-net' bargain Graham's enterprising bar sets
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 51
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 50
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 34
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 17
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 13
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 13
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 0
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 15%
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🔴 0
Liquidity position Bagehot would flag as a real risk
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 285 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (6 bullish · 3 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
-1813.6%
Operating Margin
-19540.0%
Net Margin
-17634.4%
EBITDA Margin
-17954.6%
ROE
-25.6%
ROA
-13.2%
ROIC
—
EPS
-$4.16
Cash
$899.78K
Total Debt
—
Current Ratio
0.17
Debt/Equity
—
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$15.43
Tangible Book Value per Share (Tangible NAV)
-$13.00
Sentiment based on basic keywords (not AI) — 3 positive, 0 neutral, 3 negative out of the last 6 articles.
Benzinga · 8.9.2026
Benzinga · 4.9.2026
Yahoo · 31.8.2026
Exec Edge · 31.8.2026
Benzinga · 21.8.2026
Benzinga · 19.8.2026
GridAI Technologies Corp. (GRDX) currently has a StockIQ AI score of 49/100, rated "Moderate" (a partial score — based on only 6 of 7 categories, some data is currently unavailable). The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
GRDX currently scores 49/100 (Moderate) across the categories we measure (a partial score — based on only 6 of 7 categories, some data is currently unavailable). StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
GRDX's technical score is 67/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 74.0%; Net income growth: 64.6%; Price is above the 50-day average.
Based on the real signals StockIQ computed: Operating margin: -19540.0% (negative); Net margin: -17634.4% (negative); ATR: 11.1% of price.
StockIQ has no recorded dividend payment history for GRDX.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 7 sales out of the last 19 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Sawyer Jason David | Grant/Award from Employer | 30.6.2026 | 250,000 | +250,000 | — |
| Sawyer Jason David | Grant/Award from Employer | 30.6.2026 | 540,000 | +250,000 | — |
| Sawyer Jason David | Grant/Award from Employer | 31.3.2026 | 250,000 | +250,000 | — |
| Sawyer Jason David | Grant/Award from Employer | 31.3.2026 | 290,000 | +250,000 | — |
| Pursglove Geordan Garrett | Grant/Award from Employer | 1.1.2026 | 40,000 | +40,000 | — |
| Uppal Manpreet | Grant/Award from Employer | 1.1.2026 | 40,000 | +40,000 | — |
| Syage Jack | Grant/Award from Employer | 1.1.2026 | 40,000 | +40,000 | — |
| BORKOWSKI EDWARD | Grant/Award from Employer | 1.1.2026 | 40,000 | +40,000 | — |
| Syage Jack | Grant/Award from Employer | 1.1.2026 | 40,000 | +40,000 | — |
| Sawyer Jason David | Grant/Award from Employer | 22.12.2025 | 40,000 | +40,000 | — |
| Skowron Anna | Grant/Award from Employer | 22.12.2025 | 65,000 | +65,000 | — |
| Romano Sarah | Open Market Sale | 6.1.2025 | 727 | -727 | $0.64 |
| Romano Sarah | Open Market Sale | 9.10.2024 | 476 | -476 | $0.45 |
| Romano Sarah | Open Market Sale | 2.7.2024 | 621 | -621 | $1.07 |
| SAPIRSTEIN JAMES | Open Market Sale | 2.7.2024 | 1,289 | -1,289 | $1.07 |
| KHOSLA CHAITAN PHD | Grant/Award from Employer | 11.6.2024 | 24,889 | +24,889 | — |
| Romano Sarah | Open Market Sale | 1.4.2024 | 75 | -75 | $4.23 |
| SAPIRSTEIN JAMES | Open Market Sale | 1.4.2024 | 174 | -174 | $4.23 |
| SAPIRSTEIN JAMES | Open Market Sale | 15.3.2024 | 1,887 | -1,887 | $4.96 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
54,523 shares short as of 2026-09-15 · vs. 65,966 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
31.5% of trading volume this week was short selling, vs. 32.2% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology